Programme
Best of ASCO® in Slovakia 2010

AMERICAN SOCIETY OF CLINICAL ONCOLOGY
SLOVAK ONCOLOGY SOCIETY

www.asco.org/boaintl

Best of ASCO®
A program licensed by the American Society of Clinical Oncology

Annual Meeting ’10

SLS
SLOVENSKÁ LEKÁRSKA SPOLOČNOSŤ

POKO
MEDICAL EDUCATION
Programme “Best of ASCO® Slovakia 2010”

7.30
Registration

8.30 – 8.45
Welcome

8.45 – 10.15
Breast Cancer Session
Chairmen: Ivan Koza, Mária Wágnerová

8.45 – 9.15
Breast Cancer – Prognostic/Predictive and Local Therapy (Igor Andrašina)

1. Krag, D. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.
2. Giuliano, A. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2N0M0 breast cancer who have a positive sentinel node.
3. Hughes, K. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer.
4. Ribi, K. Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.
5. Cote, R. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer.
6. Dezentje, V. Pharmacogenetics of tamoxifen in relation to disease-free survival in a dutch cohort of the tamoxifen exemestan adjuvant multinational (TEAM) trial.
7. Tang, G. Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.
8. Bonnefoi, H. Phase III trial (EORTC 10994/ BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis.

9.15 – 9.45
Breast Cancer – Metastatic
(Stanislav Špánik)

3. Twelves, C. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.
4. Karlsson, E. Discordance in hormone receptor status in breast cancer during tumor progression.
5. Locatelli, M. A. Should liver metastases of breast cancer be biopsied to improve treatment choice?
6. O’Shaughnessy, J. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).
Programme “Best of ASCO® Slovakia 2010”

9.45 – 10.15
Discussion

10.15 – 10.30
Coffee break

10.30 – 12.00
Lung Cancer and Genitourinary Cancer Session
Chairmen: Peter Beržinec, Jozef Mardiak

10.30 – 11.00
Lung Cancer (Lawrence H. Einhorn)

1. Cuileanu, TE. Randomized phase 3 study (SPEAR) of picoplatin + best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after 1st-line platinum-based chemotherapy.


3. Quoix, E. Weekly paclitaxel combined with monthly carboplatin versus single agent therapy in patients aged 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).


5. Bang, YJ. Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK positive patients with non small cell lung cancer (NSCLC).


7. Fidias, P. A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC).

8. Schiller, JH. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

11.00 – 11.30
Genitourinary Cancer (Jozef Mardiak)


3. De Bono, J. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).

4. Warde, P. Intergroup randomized phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633).

5. Mottet, N. Impact of radiotherapy (RT) combined with androgen deprivation (ADT) vs ADT alone for local control in clinically locally advanced prostate cancer.

11.30 – 12.00
Discussion
Programme “Best of ASCO® Slovakia 2010”

12.00 – 13.00
Hematologic
Malignancies Session
Chairman: Andrej Vranovský

12.00 – 12.30
Hematologic Malignancies (Ján Gyárfáš)
2. Thiel, E. Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The g-PCNSL-SG1 randomized phase IV trial.
3. Fiore, F. Early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma improves the overall treatment outcome of ABVD.
6. Boccardo, M. Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients.
8. Larson, R. Nilotinib is superior to imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond 1 year.

12.30 – 13.00
Discussion

13.00 – 14.00
Lunch

14.00 – 16.00
Gastrointestinal
and Varia Session
Chairmen: Jiří Tomášek, Juraj Beniak

14.00 – 14.30
Gastrointestinal Colorectal Cancer (Jiří Tomášek)
1. Tabernero, J. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).
2. Goldberg, R. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup phase III trial N0147.
3. Maughan, T. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.
4. Roth, A. Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial.
5. Alberts, S. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147

14.30 – 15.00
Gastrointestinal Noncolorectal Cancer
(Zuzana Hlavatá)


2. Nicoli, P. Updated safety and efficacy results of the phase III trial of sunitinib (SU) vs placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET).

3. Gaast, A. Preoperative concurrent chemoradiotherapy improves survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicentre randomized phase III study.


5. Marten, A. Multi-center phase III trial of posoperative cisplatin, interferon alpha-2b, and5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma (CapRI trial).

15.00 – 15.30
Patient and Survivor Care
(Juraj Beniak)

1. Mustian, K. YOCAS® yoga significantly improves sleep, fatigue and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors.


4. Bordeleau, L. A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.


15.30 – 16.00
Discussion

16.00 – 16.15
Coffee Break

16.15 – 17.45
Gynecologic Cancer,
Head and Neck Cancer
and Melanoma Session
Chairmen: Tibor Packáň, Vladimír Malec

16.15 – 16.45
Head and Neck Cancer and Melanoma
(Dagmar Sorkovská)

1. Wells, S. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA).

2. Ang, KK. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and
Programme “Best of ASCO® Slovakia 2010”

neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome.
3. Gillison, M. Analysis of the effect of p16 and tobacco pack-years (p-y) on overall survival (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in radiation therapy oncology group (RTOG) protocol 9003.
5. O’Day S. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. Study MDX010-20.

16.45 – 17.15
Gynecologic Cancer (Richard Hrubý)
2. Lu, K. A prospective u.s. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA).
3. Karlan, B. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.
4. Teneriello, M. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by elective paclitaxel consolidation in advanced ovarian cancer:

Final safety and efficacy report.
5. Pignata, S. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Efficacy results of the MITO-2 randomized multicenter trial.
7. Ray-Coquard, I. Increased risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment – a french sarcoma group.
8. Verschraegen, C. A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO).

17.15 – 17.45
Discussion
17.45 – 18.00
Farewell
Všeobecné informácie / General Information

Organizátor / Organizer:
POKO Poprad, s. r. o.,
Slovenská onkologická spoločnosť Slovenskej lekárskej spoločnosti

Termin / Date:
25. september 2010 / 25th September 2010

Miesto / Place:
Holiday Inn, Bajkalská 25/A, Bratislava

Organizačný výbor / Organizing Committee:
MUDr. Juraj BENIAK, POKO Poprad, Slovakia
MUDr. Marián KARALEJČÍK, POKO Poprad, Slovakia
doc. Jozef MARDIAK, CSc. NOÚ, Bratislava, Slovakia
MUDr. Mária REČKOVÁ, POKO Poprad, Slovakia

Predsedajúci, prednášajúci / Faculty:
doc. MUDr. Igor ANDRAŠINA, CSc., VOÚ, Košice, Slovakia
MUDr. Juraj BENIAK, POKO Poprad, Slovakia
doc. MUDr. Peter BERŽINEC, CSc., OÚtaRH, Nitra, Slovakia
prof. Lawrence H. EINHORN, Indiana University Simon Cancer Center, Indianapolis, USA
MUDr. Ján GYÁRFÁŠ, NOÚ, Bratislava, Slovakia
MUDr. Zuzana Hlavatá, NOÚ, Bratislava, Slovakia
MUDr. Richard HRUBÝ, PhD., FNsP, Žilina, Slovakia
prof. MUDr. Ivan KOZA, DrSc., NOÚ, Bratislava, Slovakia
MUDr. Vladimír MALEC, PhD., FNsP, Banská Bystrica, Slovakia
doc. MUDr. Jozef MARDIAK, CSc., NOÚ, Bratislava, Slovakia
MUDr. Tibor PACKÁN, Ph.D., VOU, Košice, Slovakia
MUDr. Dagmar SORKOVSKÁ, OÚSA, Bratislava, Slovakia
prof. MUDr. Stanislav ŠPÁNK, CSc., OÚSA, Bratislava, Slovakia
MUDr. Jiří TOMÁŠEK, Masarykův onkologický ústav, Brno, Czech Republic
MUDr. Andrej VRANOVSKÝ, PhD., NOÚ, Bratislava, Slovakia
doc. MUDr. Mária WÁGNEROVÁ, CSc., VOÚ, Košice, Slovakia

Oficiálny kongresový jazyk / Official conference language:
slovenčina, angličtina / Slovak, English.

Organizačné zabezpečenie / Organizational Management:
SOLEN, s. r. o., Lovinského 16, 811 04 Bratislava

V prípade záujmu o účasť vyplnenú prihlášku poštou, faxom, e-mailom na adresu: Completed applications of attendance may be sent by mail, fax or e-mail to the following address:

Michaela Malová, SOLEN, s.r.o. Lovinského 16, 811 04 Bratislava
tel.: 02/5465 1385, fax: 02/5465 1384, malova@solen.sk, www.solen.sk

Podujatie bude ohodnotené 7 CME kreditmi. / The attendees will receive 7 CME credits.
Priezvisko, meno, titul (čítateľne):
Surname, Name, Title (legibly):

adresa pracoviska:
Work Address:

Tel., fax:                                        e-mail:

Reg. č. Slovenskej lekárske komory:
Reg. Number of the Slovak medical chamber:

Záväzná objednávka ubytovania v Hoteli Holiday Inn / Obligatory order of the accommodation in the Holiday Inn
(ubytovanie si hradí sám účastník na recepcii hotela / the accommodation is paid by the attendee at the hotel reception)

dvojlôžková izba – 109 €
(double room – 109 €)

Mám záujem o ubytovanie z 24. na 25. 9. 2010
I would like to book a room from 24th till 25th of September 2010

áno/Yes                   nie/No

Chcem byť ubytovaný(á) s:
I would like to share a room with:

Týmto dávam súhlas
I herein give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution of information emails according to the act No. 428/2002. The act No. 482/2002 deals with security of personal data.

Podpis/signature:


The deadline for application is 9th of September 2010 (accommodation) or 18th of September 2010 (attendance).